(Q73269099)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

D Mavroudis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A Alexopoulos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

N Ziras

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

N Malamos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

C Kouroussis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S Kakolyris

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S Agelaki

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

K Kalbakis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

N Tsavaris

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A Potamianou

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

G Rigatos

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

V Georgoulias

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 October 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

1249-1254

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

Taxanes in the treatment of breast cancer: a prodigy comes of age.

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

1 reference

7 January 2021

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008351310818

7 January 2021

Identifiers

DOI

10.1023/A:1008351310818

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11106112%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference